ACT-389949
(ACT389949) manufacturers
- ACT-389949
-
- $81.00
-
2026-07-22
- CAS:1258417-54-7
- Purity: 99.40%
- Supply Ability: 10g
- ACT-389949
-
- $81.00
-
2026-07-22
- CAS:1258417-54-7
- Purity: 99.40%
- Supply Ability: 10g
- ACT-389949
-
- $98.00
-
2025-06-10
- CAS:1258417-54-7
- Purity: 99.40%
- Supply Ability: 10g
|
| | ACT-389949
(ACT389949) Basic information |
| Product Name: | ACT-389949
(ACT389949) | | Synonyms: | ACT-389949
(ACT389949);2-methyl-5-m-tolyloxazol-4-carboxylic acid {2-[4-(1,1-difluoroethyl)-oxazol-2-ylmethyl]-2H-[1,2,3]triazol-4-yl}amide;4-Oxazolecarboxamide, N-[2-[[4-(1,1-difluoroethyl)-2-oxazolyl]methyl]-2H-1,2,3-triazol-4-yl]-2-methyl-5-(3-methylphenyl)-;N-[2-[[4-(1,1-difluoroethyl)-1,3-oxazol-2-yl]methyl]triazol-4-yl]-2-methyl-5-(3-methylphenyl)-1,3-oxazole-4-carboxamide;5-Pyridinebutanoicacid,α,γ-dioxo-,methylester;N-(2-((4-(1,1-Difluoroethyl)oxazol-2-yl)methyl)-2H-1,2,3-triazol-4-yl)-2-methyl-5-(m-tolyl)oxazole-4-carboxamide;inhibit,ACT389949,Inhibitor,ACT 389949,ACT-389949;N-2-4-(1,1-Difluoro-ethyl)-2-oxazolylmethyl-2H-1,2,3-triazol-4-yl-2-methyl-5-(3-methylphenyl)-4-oxazolecarboxamide | | CAS: | 1258417-54-7 | | MF: | C20H18F2N6O3 | | MW: | 428.39 | | EINECS: | | | Product Categories: | API | | Mol File: | 1258417-54-7.mol |  |
| | ACT-389949
(ACT389949) Chemical Properties |
| form | Solid | | color | Off-white to yellow |
| | ACT-389949
(ACT389949) Usage And Synthesis |
| Uses | ACT-389949 is a first-in-class, potent and selective and agonist of formyl peptide receptor type 2 (FPR2)/Lipoxin A4 receptor (ALX), with an EC50 of 3 nM for FPR2/ALX internalization into monocytes. ACT-389949 has potential for the treatment of inflammatory disorders[1][2]. | | in vivo | ACT-389949 has well tolerated. Maximum concentrations are reached around 2 hours after dosing, with a mean terminal half-life of 29.3 hours[1].
Administration of ACT-389949 results in a dose-dependent, long-lasting internalization of FPR2/ALX into leukocytes[1].
| | References | [1] Stalder AK,et al. Biomarker-guided clinical development of the first-in-class anti-inflammatory FPR2/ALX agonist ACT-389949. Br J Clin Pharmacol. 2017 Mar;83(3):476-486. DOI:10.1111/bcp.13149
[2] Lind S, et al. Functional and signaling characterization of the neutrophil FPR2 selective agonist Act-389949. Biochem Pharmacol. 2019 Aug;166:163-173. DOI:10.1016/j.bcp.2019.04.030 |
| | ACT-389949
(ACT389949) Preparation Products And Raw materials |
|